The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34923824

about

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma Idelalisib for the treatment of chronic lymphocytic leukemia Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia The biology behind PI3K inhibition in chronic lymphocytic leukaemia CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).Initial treatment of CLL: integrating biology and functional status.Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma.Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse.Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.Combining immunotherapy and targeted therapies in cancer treatment.Targeting the B cell receptor pathway in chronic lymphocytic leukemia.Lenalidomide alone and in combination for chronic lymphocytic leukemia.Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.Phosphoinositide 3-kinase inhibitors in lymphoma.Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.An overview of quinoline as a privileged scaffold in cancer drug discovery.Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.

P2860

Q26865645-5EADD4D2-459A-431E-B50E-FF980918A5C1 Q27015826-E3275C74-731B-4F2C-8A6D-CD283E8BDB83 Q27025812-6037ACD7-7018-4952-A6D1-0426FF26537C Q27674083-2D382525-4EF9-4E8C-91EC-DA35DF4A583F Q28083266-EB24F03D-ADBB-4026-AC07-173DF0066104 Q30383411-50CC5A73-0644-47A9-83F2-5357D21AA489 Q33413834-D17D11EB-5B0A-4D61-B124-4B04005A5926 Q33690142-BDECD7C3-8E3C-4B10-A4C7-B0B6A2CA3A7A Q34008584-B68E9159-4B0C-43F9-9DF9-8E7F43BAB3C7 Q34081881-E6D3CFCC-4703-4EB6-9F64-7818CCB40311 Q34106863-1DFAC894-BA3C-4A02-8225-27C6F6F238E0 Q34260622-82571F64-BB58-4DDF-91AE-D57797B95DD2 Q34625543-B6C3720F-7D2B-4F49-9C09-B49B6768A8D3 Q34663617-AB42E40D-BB0F-4012-B877-A72B25F9A4A3 Q36219647-C89AC0CE-31D8-48A6-8A04-A7C2B5A8D939 Q36462375-080D3576-40D3-43B6-B4A3-692A1156EDE9 Q36498356-2A906C6E-8B6F-47B9-A7D4-4B64A6B9F646 Q36685569-AB2CE3C4-C7D6-4BDD-8529-A2531294E659 Q36725307-43C66F2A-4CEE-4E8C-B179-2B44143A097F Q36737287-6EF3B1CC-8D35-41E2-8EDB-77DE54C3740C Q36862781-85FEBB75-34F1-4AB6-B2A3-65DA2280FE6E Q37010509-621C6381-C4BB-41E9-A680-7B5FB100C146 Q37610087-C3D99574-4FCF-4988-B601-9412C4804D2B Q37747342-281421FE-5A41-4DD2-B0FF-65EEAA080DE2 Q37951937-4749C262-BAF7-40ED-910C-8319C2DC68AB Q37958036-719CD9EA-9FAA-49BD-B066-71A86DA68502 Q37960157-BB5EDBB6-4DC3-4BD2-9BFA-F2F5C96FEA21 Q37995939-3126E356-3B68-447F-81E5-10751BB870EF Q38012179-F3D7016B-B6C6-44B0-9F35-BED1547C9D59 Q38068736-5211DEF9-226E-40C4-BD58-EB7E93BC0C9A Q38069567-60E1D200-4C4B-4369-9176-0847C50B602F Q38193070-D4763D47-0DE1-4A52-96F7-8990DD5F760C Q38229531-B149F815-7218-4DA5-B0A7-1D41E34EA17F Q38560740-EFFED5ED-A8B0-4675-9BC8-989B9EB27429 Q38764077-DD74045E-0428-4373-830C-87E0E3D17253 Q38852858-67C0BF6B-D07F-4F4E-A83B-EEFCEE4D465C Q39121775-7DD90271-CB93-4540-A452-91F16AEA06B7 Q39235281-AAAD25DE-C66E-46C9-901F-B9EB861FD324 Q40234174-6F9AD7E4-88CE-4DED-8EEA-E04E5C320032 Q42087653-B7D18E2D-FA2B-4410-8971-CEC326DA5AB7

P2860

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q34923824

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@ast

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@en

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@nl

type

label

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@ast

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@en

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@nl

prefLabel

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@ast

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@en

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@nl

P1433

Q34923824-6C6D4505-763E-44FD-A7AA-9717C30C5446

P1476

Q34923824-F676A965-5495-4629-A2AE-0FE41B43245A

P2093

Q34923824-55D1ABA3-8BC5-41C0-8304-0E6D144ED522

Q34923824-7FA40B13-B9B7-4D2F-9056-E7A31F049920

Q34923824-7FCE61B2-D302-4C6B-BF42-BEAB212BA4CE

Q34923824-8ACB3276-C262-4B17-B3CA-78E9DBF3FE57

Q34923824-AF13F8EE-8D45-4FFC-8A03-6854D568A8B0

Q34923824-C645F193-1EAF-4ABD-AF72-A29D9BBE1830

Q34923824-C67525C5-64E3-4F94-AAA4-24827577C5EB

Q34923824-CF397183-F5FE-4625-9899-C24CE7D17D46

Q34923824-D13780D7-B792-4D77-9978-376FD07A4271

Q34923824-E442A853-775F-48DB-8610-C79259FC5BFE

P2860

Q34923824-01F9AF11-6161-4BE9-9FB5-95D39F332580

Q34923824-0D46B098-C186-429F-82C0-A601D8B01715

Q34923824-1ADBB972-A2A3-46D0-B189-9D0EDD10A29E

Q34923824-45C53C9E-7985-4C3A-B4E3-8A9A03327413

Q34923824-5D92DC59-7227-4899-A3FE-C7989ECCD25B

Q34923824-6187AE9F-F742-4996-9974-FAF582A884D6

Q34923824-6263028F-57EA-4035-A29E-36D3D6831271

Q34923824-74750A6A-DFFD-4FD4-9B66-B3F5AC4B1B59

Q34923824-7DBB51C9-6E53-40C7-A1E6-8A370E0A0328

Q34923824-929FECCD-540B-480B-AA0D-B35734021CEF

P304

Q34923824-C3AB0DCD-0C6B-433F-8619-3D0F36A43CC1

P31

Q34923824-49B9C6FF-AE3A-4697-9BAA-F4A59855F5DD

P356

Q34923824-F32D4AD0-F833-45C6-AAF0-BBD621DA7D5B

P407

Q34923824-1266837C-9F60-4AE3-AA4E-B3C7F18402FF

P433

Q34923824-5562D1A7-1B0B-4FB0-9447-D1434A125484

P478

Q34923824-77BD0064-C547-4ECB-AB50-030B3980BBE0

P50

Q34923824-656E5FA2-A941-41B2-9F15-91B190D77895

P577

Q34923824-01EC2571-8615-467C-B25B-B1B4E48D909D

P5875

Q34923824-C908C093-3EF9-4B55-8E42-2D2C663C0768

P698

Q34923824-2A393D31-B5A3-4C4C-98A3-6EF162F80094

P921

Q34923824-785B6A9C-702F-4B82-BA28-94A163369567

Q34923824-AA2B9EDA-6CDF-4EB3-AB22-ECDA51D6F302

P932

Q34923824-F9956B10-247A-4C73-8AB6-A9865DADC250

P356

BLOOD-2010-11-315705

P1433

P1476

The role of phosphatidylinosit ...... chronic lymphocytic leukemia.

@en

P2093

Amber L Gordon

http://www.w3.org/2001/XMLSchema#string

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Asha Ramanunni

http://www.w3.org/2001/XMLSchema#string

Brian J Lannutti

http://www.w3.org/2001/XMLSchema#string

Jeffrey Jones

http://www.w3.org/2001/XMLSchema#string

Kamal D Puri

http://www.w3.org/2001/XMLSchema#string

Kristie A Blum

http://www.w3.org/2001/XMLSchema#string

Natarajan Muthusamy

http://www.w3.org/2001/XMLSchema#string

Rosa Lapalombella

http://www.w3.org/2001/XMLSchema#string

Sarah E M Herman

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Expression of the human B-cell surface protein CD20: alteration by phorbol 12-myristate 13-acetate.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

P304

4323-4327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-11-315705

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50289461

http://www.w3.org/2001/XMLSchema#string

P698

21378270

http://www.w3.org/2001/XMLSchema#string

P921

P932

3087482

http://www.w3.org/2001/XMLSchema#string